首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子

Recombinant Human BMP2 protein

  • 中文名: 骨成型蛋白2(BMP2)重组蛋白
  • 别    名: BMP2;BMP2A;Bone morphogenetic protein 2
货号: PA1000-349DB
Price: ¥询价
数量:
大包装询价

产品详情

纯度> 95 % SDS-PAGE.
种属Human
靶点BMP2
Uniprot NoP12643
内毒素< 0.01EU/μg
表达宿主E.coli
表达区间283-396aa
氨基酸序列MQAKHKQRKR LKSSCKRHPL YVDFSDVGWN DWIVAPPGYH AFYCHGECPF PLADHLNSTN HAIVQTLVNS VNSKIPKACC VPTELSAISM LYLDENEKVV LKNYQDMVVE GCGCR
预测分子量13 kDa
蛋白标签His tag N-Terminus
缓冲液PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt.
Reconstituted protein solution can be stored at 2-8°C for 2-7 days.
Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100μg/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于BMP2重组蛋白的3篇代表性文献及其摘要内容:

---

1. **文献名称**:**"Novel regulators of bone formation: Molecular clones and activities"**

**作者**:Wozney JM, Rosen V, Celeste AJ, et al.

**摘要**:该研究首次报道了人BMP2基因的克隆及其重组蛋白的制备。通过体外实验证明,重组BMP2可诱导未分化间充质细胞向成骨细胞分化,并在动物模型中促进骨缺损修复,奠定了BMP2在骨再生领域的应用基础。

2. **文献名称**:**"Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures"**

**作者**:Govender S, Csimma C, Genant HK, et al.

**摘要**:通过多中心临床试验评估重组BMP2联合胶原载体治疗开放性胫骨骨折的效果。结果显示,与对照组相比,BMP2显著加速骨折愈合,降低二次手术率,验证了其在创伤骨科中的临床应用潜力。

3. **文献名称**:**"Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in spinal fusion"**

**作者**:Burkus JK, Gornet MF, Dickman CA, et al.

**摘要**:研究分析了BMP2在脊柱融合术中的疗效与安全性。尽管BMP2能提高融合成功率并缩短康复时间,但也指出其可能引发异位骨化、炎症反应等副作用,强调需权衡临床收益与风险。

---

以上文献涵盖BMP2重组蛋白的分子机制、临床应用及潜在问题,为相关研究提供关键参考。如需具体期刊信息或年份,可进一步补充。

背景信息

**Background of BMP2 Recombinant Protein**

Bone Morphogenetic Protein 2 (BMP2), a member of the transforming growth factor-beta (TGF-β) superfamily, is a critical signaling molecule involved in embryonic development, skeletal formation, and tissue homeostasis. Initially identified for its ability to induce bone and cartilage formation, BMP2 regulates cell proliferation, differentiation, and apoptosis through binding to transmembrane serine/threonine kinase receptors, activating SMAD-dependent and non-SMAD signaling pathways. Its role in osteogenesis has made it a focal point in regenerative medicine, particularly for treating bone defects and fractures.

Recombinant BMP2 (rhBMP2) is produced using biotechnological methods, such as expression in *E. coli* or mammalian cell systems, followed by purification to ensure biological activity. Unlike native BMP2. the recombinant form offers controlled production, high purity, and scalability, making it suitable for clinical applications.

Clinically, rhBMP2 is FDA-approved for spinal fusion and open tibial fractures, where it promotes bone regeneration by recruiting mesenchymal stem cells and stimulating osteoblast differentiation. It is often delivered via absorbable collagen scaffolds to localize its activity. However, challenges remain, including high doses leading to adverse effects (e.g., inflammation, ectopic bone formation) and cost-related limitations.

Research continues to optimize rhBMP2 delivery systems, dose efficiency, and combinatorial therapies with growth factors or biomaterials to enhance safety and efficacy. Its applications also extend beyond orthopedics, showing potential in dentistry, cartilage repair, and even cancer therapy studies. Despite controversies, rhBMP2 remains a cornerstone in bone tissue engineering, underscoring the intersection of developmental biology and translational medicine.

客户数据及评论

折叠内容

大包装询价

×